ScienceDaily (Dec. 1, 2009) — The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -- produced from healthy and tumour cells from the patient him or herself -- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours. The new therapy is administered to participating patients combined with the standard, first-line treatment involving surgical extirpation of the tumour followed by radiotherapy and chemotherapy treatment with temozolomide.
